HIV Integrase Inhibitor Pharmacogenetics and Clinical Outcomes: An Exploratory Association Study
As HIV is now primarily a chronic condition, treatment is given life-long with changes as necessitated by alterations in tolerability and efficacy. Thus, personalized medicine may be useful in the prevention of unnecessary drug exposure and avoidable side effects. Three of the four currently availab...
Main Author: | Murrell, Derek E |
---|---|
Format: | Others |
Language: | English |
Published: |
Digital Commons @ East Tennessee State University
2018
|
Subjects: | |
Online Access: | https://dc.etsu.edu/etd/3465 https://dc.etsu.edu/cgi/viewcontent.cgi?article=4926&context=etd |
Similar Items
-
Multiple choices for HIV therapy with integrase strand transfer inhibitors
by: Raffi Francois, et al.
Published: (2012-12-01) -
Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals
by: Pablo López, et al.
Published: (2021-03-01) -
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
by: Nicola Gianotti, et al.
Published: (2017-11-01) -
Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
by: Thibault Mesplède, et al.
Published: (2015-07-01) -
HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?
by: Vogel Martin, et al.
Published: (2009-11-01)